ETON
Eton Pharmaceuticals·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 3
MACD Golden Cross
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ETON
Eton Pharmaceuticals, Inc.
An innovative pharmaceutical company that having a product portfolio in Orphan Drugs, Hospital Products, and Royalty Products
21925 W. Field Parkway, Suite 235, Deer Park, IL 60010-7278
--
Eton Pharmaceuticals, Inc. was incorporated under the laws of the State of Delaware on April 27, 2017. The Company is an innovative pharmaceutical company focused on developing, acquiring and commercializing innovative products to meet the unmet needs of patients with rare diseases. The company currently has four commercial rare disease products, ALKINDI SPRINKLE for the treatment of adrenal insufficiency, glutamate for the treatment of hyperammonemia caused by deficiency of N-acetylglutamate synthase; betaine anhydrous for the treatment of homocysteinuria; nitticinone for the treatment of type 1 hereditary tyrosinemia, and three other product candidates are in late-stage development. The company is developing dehydrated alcohol injection, which has obtained orphan drug status for the treatment of methanol poisoning, ZENEO hydrocortisone auto-injector and ET-400 for the treatment of adrenal crisis.
Company Financials
EPS
ETON has released its 2025 Q3 earnings. EPS was reported at 0.04, versus the expected 0.16, missing expectations. The chart below visualizes how ETON has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
ETON has released its 2025 Q3 earnings report, with revenue of 22.46M, reflecting a YoY change of 117.54%, and net profit of -1.93M, showing a YoY change of -407.34%. The Sankey diagram below clearly presents ETON's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
